Will the FDA approve CagriSema for weight management before 31 December 2026?

• What pushes it up. The NDA was filed in December 2025, placing the expected PDUFA decision date in the fourth quarter of 2026 [1].
• What pushes it up. Head-to-head Phase 3 data released in September 2026 showed CagriSema achieved greater weight loss than Eli Lilly's tirzepatide in patients with type 2 diabetes [1, 5].
• What pushes it up. Recent industry reports describe the FDA decision as 'near' as of early October 2026 [10].
• What pushes it up. CagriSema is a combination of semaglutide (already FDA-approved) and cagrilintide, which may streamline the review process compared to a completely novel molecular entity.
• What pushes it down. The pivotal REDEFINE-1 trial missed Novo Nordisk's internal target of 25% weight loss, which the CEO characterized as part of 'mixed data' and 'setbacks' [1, 2].
• What pushes it down. The proximity of the expected decision to the December 31 deadline leaves no margin for a standard 3-month PDUFA extension, which is often triggered by the submission of major late-cycle data [1, 2].
• What pushes it down. A Complete Response Letter (CRL) or any administrative delay would result in a 'No' resolution for this specific timeframe.
• What pushes it down. There are three serious safety signals for cagrilintide recorded in the FAERS database, which may prompt additional regulatory scrutiny [FAERS Context].
• What would move this number most. Whether the 'mixed' results from the REDEFINE-1 trial or the late-stage data releases in August/September 2026 led to a major amendment of the NDA, which would automatically push the PDUFA date into early 2027.

• What pushes it up. Positive efficacy data showing greater weight loss than Lilly rival (Reuters) [tier 2]
• What pushes it up. Reports of superior weight loss in late‑stage diabetes trial (Pharmaceutical Executive) [tier 3]
• What pushes it down. Novo reports “couple of setbacks” in R&D and mixed data (Fierce Biotech) [tier 2]
• What pushes it down. Submaximal dose results suggest less than expected efficacy (Pharmaceutical Technology) [tier 3]
• What would move this number most. The official PDUFA date or any FDA communication confirming the review timeline would most shift the estimate.

• What pushes it up. Positive trial data and strong Novo track record, as reported by Reuters [tier 2] and Pharmaceutical Executive [tier 3]
• What pushes it up. NDA filed and review scheduled for 2026, indicating FDA intent to evaluate the product [tier 1]
• What pushes it down. Mixed data and missed weight‑loss target in REDEFINE‑1, reported by Pharmaceutical Technology [tier 3]
• What pushes it down. Safety signals in FAERS and industry concerns about potential regulatory delays, highlighted by Fierce Biotech and Investir Les Echos [tier 2]
• What would move this number most. Whether the FDA will issue a complete response letter or postpone the PDUFA date, which would delay or prevent approval by 31 Dec 2026.

• What pushes it up. Industry trackers place the decision in Q4 2026, suggesting a higher likelihood of approval by the deadline. [tier 4]
• What pushes it up. The NDA was filed on 18 Dec 2025 with a review scheduled in 2026, indicating the drug is in the first review cycle. [tier 4]
• What pushes it down. No official PDUFA date has been released, and the FDA has not yet issued a decision. [tier 4]
• What pushes it down. The lack of tier 1 or tier 2 confirmation means the information is weak and could be inaccurate. [tier 4]
• What would move this number most. The official PDUFA date and the actual FDA decision by 31 Dec 2026.

• What pushes it up. The NDA was submitted on 18 December 2025 and accepted for review, keeping an official decision window within Q4 2026 [tier 1]
• What pushes it up. CagriSema builds on semaglutide, an already FDA-approved moiety with an established safety profile [tier 1]
• What pushes it down. REDEFINE-1 missed its internal target of 25% weight loss, which could complicate label discussions or clinical evaluation [tier 1]
• What pushes it down. Any PDUFA extension or Complete Response Letter (CRL) before 31 December 2026 automatically results in a NO outcome [tier 1]
• What would move this number most. Whether the FDA issues a decision within the standard 10-month review window without requiring additional data or extending the PDUFA date into 2027.

Reasons not recorded for this revision (detailed history has only been kept since recently).

Reasons not recorded for this revision (detailed history has only been kept since recently).